deltatrials
Completed PHASE2/PHASE3 NCT00345501

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure

Sponsor: Onassis Cardiac Surgery Centre

Conditions Angioplasty, Transluminal, Percutaneous Coronary Coronary Angiography Renal Insufficiency, Chronic
Interventions Iloprost Placebo
Updated 5 times since 2017 Last updated: Aug 22, 2007 Started: Nov 30, 2005 Completion: Jul 31, 2007

This PHASE2/PHASE3 trial investigates Angioplasty, Transluminal, Percutaneous Coronary and Coronary Angiography and is currently completed. Onassis Cardiac Surgery Centre leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Onassis Cardiac Surgery Centre
Data source: Onassis Cardiac Surgery Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Athens, Greece